8　付録

- 死亡に至った有害事象　Listing 16.2.7.1.3.2
- 重篤な有害事象の一覧表　Listing 16.2.7.1.2.2

Listing 16.2.7.1.3.2
Adverse Events (AEs) Leading to Death
Safety Set

Patient ID: [redacted] - [redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/Asian/17[redacted] cm/9[redacted].8 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 脳出血 CEREBRAL HEMORRHAGE	1	RCP (145)/ 145/ 145	Y	DTH, HOS, OTH	GRADE 5	NR/ NC/ FATL	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.3.2
Adverse Events (AEs) Leading to Death
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/16[redacted].5 cm/11[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 COVID-19 COVID-19 INFECTION	1	OLE (216)/ 33/ 33	Y	DTH	GRADE 5	NR/ NA/ FATL	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.3.2
Adverse Events (AEs) Leading to Death
Safety Set

Patient ID: [redacted] - [redacted] (Treatment Group: Ravulizumab/Male/5[redacted] years/White/18[redacted] cm/10[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ＣＯＶＩＤ－１９肺炎 COVID-19 PNEUMONIA	1	RCP (179)/ 179/ 179	Y	DTH	GRADE 5	NR/ NA/ FATL	MED; NONP; OTH: HOSPITALIZATION IN OTHER HOSPITAL, INTUBATED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.3.2
Adverse Events (AEs) Leading to Death
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/5[redacted] years/White/18[redacted] cm/12[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 COVID-19 COVID-19 INFECTION	1	OLE (379)/ 196/ 196	Y	DTH, HOS	GRADE 5	NR/ NA/ FATL	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Female/7[redacted] years/White/16[redacted] cm/8[redacted].1 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 一過性脳虚血発作 TRANSIENT ISCHEMIC ATTACK	2	RCP (159)/ 159/ 160	HOS	GRADE 3	NR/ NC/ REC	MED; NONP; OTH: PATIENT KEPT OVERNIGHT AT HOSPITAL FOR OBSERVATION
胃腸障害 悪心 NAUSEA	2	RCP (165)/ 165/ 166	HOS	GRADE 3	NR/ NC/ REC	MED; OTH: ADMITTED OVERNIGHT FOR OBSERVATION
一般・全身障害および投与部位の状態 非心臓性胸痛 NON CARDIAC CHEST PAIN	2	RCP (165)/ 165/ 166	HOS	GRADE 3	NR/ NC/ REC	OTH: OVERNIGHT HOSPITAL STAY

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/6[redacted] years/White/16[redacted] cm/8[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 脳梗塞 OBS SMALL CEREBRAL INFARCT	2	PRE (-25)/ -25/ -24	HOS	GRADE 3	NR/ NA/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Female/7[redacted] years/White/14[redacted] cm/4[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ウイルス性胃腸炎 VIRAL GASTROENTERITIS	6	RCP (79)/ 79/ 84	HOS	GRADE 3	NR/ NC/ REC	MED
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） 皮膚有棘細胞癌 SPINOCELLULAR CARCINOMA IN SITU (LEFT SUBCLAVEAR SKIN)	79	RCP (-)/ -/ 235	OTH	GRADE 2	NR/ NC/ REC	NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Female/6[redacted] years/White/16[redacted] cm/8[redacted].7 kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ AE End Date Time	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ウイルス性肺炎 VIRAL PNEUMONIA	＊約1ヵ月	OLE (317)/ 135/ -	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/6[redacted] years/White/18[redacted].4 cm/11[redacted].5 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ＲＳウイルス肺炎 PNEUMONIA DUE TO RESPIRATORY SYNCYTIAL VIRUS	5	RCP (88)/ 88/ 92	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/Asian/17[redacted] cm/9[redacted].8 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 脳出血 CEREBRAL HEMORRHAGE	8	RCP (138)/ 138/ 145	HOS	GRADE 4	NR/ NC/ REC	NONP; OTH: ＊Day 139 SURGICAL OPERATION
神経系障害 脳出血 CEREBRAL HEMORRHAGE	1	RCP (145)/ 145/ 145	DTH, HOS, OTH	GRADE 5	NR/ NC/ FATL	N

System organ classes and preferred terms were coded using 'MedDRA 24.0 '
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/- cm/9[redacted].9 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 憩室炎 DIVERTICULITIS	459	RCP (19)/ 19/ 477	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/- cm/9[redacted].8 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
胃腸障害 嚥下障害 CLINICAL DETERIORATION - SWALLOWING ISSUES	4	RCP (115)/ 115/ 118	HOS	GRADE 3	REL/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/6[redacted] years/White/18[redacted] cm/12[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 壊疽 WET GANGRENE AT THE RIGHT FOREFOOT	15	RCP (48)/ 48/ 62	HOS	GRADE 3	NR/ NC/ REC	MED; NONP
感染症および寄生虫症 ＣＯＶＩＤ－１９肺炎 COVID-19 PNEUMONIA	29	RCP (70)/ 70/ 98	HOS	GRADE 4	NR/ NC/ REC	MED; NONP
感染症および寄生虫症 感染性皮膚潰瘍 INFECTED ULCER OF THE RIGHT FOREFOOT	16	RCP (105)/ 105/ 120	HOS	GRADE 3	NR/ WTHD/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Female/3[redacted] years/Asian/16[redacted].6 cm/5[redacted].6 kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
呼吸器、胸郭および縦隔障害 労作性呼吸困難 DYSPNEA ON EXERTION	25	RCP (93)/ 93/ 117	HOS	GRADE 3	NR/ NC/ REC	MED; NONP
傷害、中毒および処置合併症 多発骨折 MULTIPLE BONE FRACTURE	*Day 117/ ONGOING	RCP (117)/ 117/ -	INCP	GRADE 2	NR/ NC/ NORC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/4[redacted] years/Asian/17[redacted].7 cm/7[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
筋骨格系および結合組織障害 腱炎 SUPPURATIVE TENDONITIS	66	RCP (62)/ 62/ 127	HOS	GRADE 3	REL/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Female/5[redacted] years/Asian/15[redacted].9 cm/4[redacted].5 kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
筋骨格系および結合組織障害 結節性変形性関節症 HEBERDEN'S NODE	*Day 150頃/ ONGOING	RCP (-)/ -/ -	HOS	GRADE 2	NR/ NC/ RCNG	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Female/6[redacted] years/Asian/15[redacted].2 cm/4[redacted].9 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） 尿管新生物 R/O LEFT UPPER URETER CANCER	3	RCP (57)/ 57/ 59	HOS	GRADE 3	NR/ NC/ REC	MED; NONP
呼吸器、胸郭および縦隔障害 呼吸困難 DYSPNEA	6	RCP (96)/ 96/ 101	HOS	GRADE 3	NR/ NC/ REC	MED; NONP
一般・全身障害および投与部位の状態 胸痛 CHEST PAIN	3	OLE (187)/ 6/ 8	HOS	GRADE 1	NR/ NC/ REC	NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Female/6[redacted] years/Asian/15[redacted].5 cm/9[redacted].6 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 帯状疱疹 HERPES ZOSTER	8	RCP (99)/ 99/ 106	HOS	GRADE 3	NR/ NC/ REC	MED
眼障害 白内障 OTHER SENILE CATARACT, RIGHT	2	OLE (302)/ 121/ 122	HOS	GRADE 2	NR/ NC/ REC	MED; NONP
傷害、中毒および処置合併症 腰椎骨折 FRACTURE OF L1 LEVEL, CLOSED	31	OLE (318)/ 137/ 167	HOS	GRADE 2	NR/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/5[redacted] years/Asian/16[redacted].1 cm/6[redacted].5 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
代謝および栄養障害 ステロイド糖尿病 WORSENING OF STEROID DIABETES	15	RCP (10)/ 10/ 24	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/6[redacted] years/White/17[redacted] cm/10[redacted].5 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 細菌性関節炎 SEPTIC ARTHRITIS OF RIGHT WRIST	22	RCP (112)/ 112/ 133	ANOM, OTH	GRADE 4	NR/ INT/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/16[redacted].5 cm/11[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ＣＯＶＩＤ－１９ COVID-19 INFECTION	13	OLE (204)/ 21/ 33	HOS	GRADE 3	NR/ NA/ REC	MED; NONP
感染症および寄生虫症 ＣＯＶＩＤ－１９ COVID-19 INFECTION	1	OLE (216)/ 33/ 33	DTH	GRADE 5	NR/ NA/ FATL	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/17[redacted].7 cm/9[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） 前立腺癌 ADENOCARCINOMA OF THE PROSTATE	64	PRE (-4)/ -4/ 60	HOS, OTH	GRADE 3	NR/ NC/ REC	NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/6[redacted] years/White/18[redacted] cm/10[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
心臓障害 うっ血性心筋症 DILATED CARDIOMYOPATHY	*Day 162/ ONGOING	RCP (162)/ 162/ -	HOS	GRADE 3	NR/ NC/ RCNG	MED; NONP
神経系障害 失神 SYNCOPE	10	RCP (162)/ 162/ 171	HOS	GRADE 3	NR/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/6[redacted] years/White/17[redacted] cm/12[redacted].4 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
一般・全身障害および投与部位の状態 全身健康状態悪化 GENERAL PHYSICAL HEALTH DETERIORATION	14	RCP (150)/ 150/ 163	OTH	GRADE 3	NR/ NC/ REC	MED
一般・全身障害および投与部位の状態 無力症 GENERALIZED WEAKNESS	14	RCP (150)/ 150/ 163	INCP, OTH	GRADE 3	NR/ NC/ REC	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Female/4[redacted] years/White/15[redacted] cm/7[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 一過性脳虚血発作 TRANSIENT ISCHEMIC ATTACK ARTERIA CAROTIS INTERNA SIN.	1	RCP (17)/ 17/ 17	HOS	GRADE 2	NR/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Female/6[redacted] years/White/16[redacted] cm/10[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
呼吸器、胸郭および縦隔障害 肺浸潤 CHRONIC INFLAMMATORY ENCAPSULATED LUNG INFILTRATION	14	RCP (64)/ 64/ 77	HOS	GRADE 2	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/5[redacted] years/White/18[redacted] cm/10[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ＣＯＶＩＤ－１９肺炎 COVID-19 PNEUMONIA	17	RCP (163)/ 163/ 179	HOS, THRT, OTH	GRADE 4	NR/ WTHD/ REC	MED; NONP; OTH: HOSPITALIZATION IN OTHER HOSPITAL, INTUBATED
感染症および寄生虫症 ブドウ球菌性敗血症 SEPSIS (STAPHYLOCOCCUS POSITIVE HEMOCULTURES)	*Day 178/ ONGOING	RCP (178)/ 178/ -	THRT	GRADE 3	NR/ NA/ NORC	N
感染症および寄生虫症 ＣＯＶＩＤ－１９肺炎 COVID-19 PNEUMONIA	1	RCP (179)/ 179/ 179	DTH	GRADE 5	NR/ NA/ FATL	MED; NONP; OTH: HOSPITALIZATION IN OTHER HOSPITAL, INTUBATED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/17[redacted].5 cm/8[redacted].7 kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
眼障害 視力障害 IMPAIRED VISION BILATERALLY	9	RCP (90)/ 90/ 98	HOS	GRADE 3	NR/ NC/ REC	N
筋骨格系および結合組織障害 椎間板突出 DISC HERNIATION AT L2 / L3 LEVEL ON THE LEFT SIDE	*Day 98/ ONGOING	RCP (98)/ 98/ -	HOS	GRADE 3	NR/ NC/ NORC	MED; NONP
神経系障害 重症筋無力症クリーゼ MG CRISIS	8	RCP (105)/ 105/ 112	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Ravulizumab/Male/7[redacted] years/White/17[redacted].5 cm/8[redacted].7 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
精神障害 自殺企図 ATTEMPTED SUICIDE	11	RCP (122)/ 122/ 132	HOS, THRT	GRADE 3	NR/ NC/ REC	NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Female/4[redacted] years/White/17[redacted] cm/9[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
傷害、中毒および処置合併症 注入に伴う反応 INFUSION REACTION	1	RCP (1)/ 1/ 1	OTH	GRADE 3	REL/ WTHD/ REC	MED; OTH: WITHDRAWAL OF IP,MEDICATION WITH DIMETINDEN 4MG IV
腎および尿路障害 腎不全 RENAL FAILURE	*Day 20/ ONGOING	RCP (20)/ 20/ -	OTH	GRADE 3	NR/ NA/ NORC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Placebo/Female/6[redacted] years/White/15[redacted].2 cm/8[redacted].5 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 帯状疱疹 HERPES ZOSTER	10	RCP (126)/ 126/ 135	OTH	GRADE 3	REL/ INT/ REC	MED; OTH: EMERGENCY DEPARTMENT VISIT

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Placebo/Female/5[redacted] years/White/14[redacted] cm/5[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
傷害、中毒および処置合併症 膝蓋骨骨折 RIGHT PATELLA FRACTURE DUE TO ACCIDENTAL FALL	42	OLE (282)/ 100/ 141	HOS	GRADE 3	NR/ NC/ REC	NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Female/7[redacted] years/White/16[redacted] cm/10[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ＣＯＶＩＤ－１９ COVID-19	4	RCP (95)/ 95/ 98	HOS	GRADE 3	NR/ NC/ REC	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Placebo/Male/8[redacted] years/Other/15[redacted] cm/7[redacted].6 kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
筋骨格系および結合組織障害 脊柱管狭窄症 SPINAL STENOSIS SECONDARY TO DEGENERATIVE DISC DISEASE	*Day 12/ ONGOING	RCP (12)/ 12/ -	HOS	GRADE 3	NR/ NC/ NORC	NONP; OTH: STILL UNDER INVESTIGATION AT THE HOSPITAL

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/5[redacted] years/White/18[redacted].3 cm/10[redacted].3 kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ AE End Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 重症筋無力症 MYASTHENIA GRAVIS EXACERBATION	4	RCP (93)/ 93/ 96	HOS	GRADE 3	NR/ NC/ REC	MED
感染症および寄生虫症 ＣＯＶＩＤ－１９の疑い SUSPECTED COVID-19	＊約2ヵ月	OLE (267)/ 85/ -	HOS, THRT	GRADE 4	NR/ NC/ REC	MED; NONP; OTH: ADMITTED
一般・全身障害および投与部位の状態 発熱 FEVER	＊約10日	OLE (295)/ 113/ -	HOS, OTH	GRADE 3	NR/ NC/ REC	MED; NONP; OTH: ADMITTED OVER NIGHT

System organ classes and preferred terms were coded using 'MedDRA 24.0 '
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Placebo/Female/7[redacted] years/White/15[redacted].9 cm/6[redacted].5 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 尿路感染 URINARY TRACT INFECTION	2	OLE (362)/ 182/ 183	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Female/5[redacted] years/Asian/15[redacted] cm/4[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
腎および尿路障害 ネフローゼ症候群 RECCURED MCD(MINIMAL CHANGE DISEASE)	11	RCP (127)/ 127/ 137	HOS	GRADE 3	NR/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Placebo/Female/6[redacted] years/White/15[redacted].5 cm/8[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 重症筋無力症 WORSENING OF MG SYMPTOMS	21	OLE (289)/ 109/ 129	HOS	GRADE 3	REL/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/8[redacted] years/White/15[redacted].4 cm/9[redacted].9 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 蜂巣炎 PERSISTENT LEFT LEG CELLULITIS	7	RCP (169)/ 169/ 175	HOS	GRADE 3	REL/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/3[redacted] years/Asian/18[redacted] cm/7[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
皮膚および皮下組織障害 皮膚肉芽腫 GRANULOMA OF SKIN	3	RCP (104)/ 104/ 106	HOS	GRADE 2	NR/ NC/ REC	MED; NONP

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/6[redacted] years/White/17[redacted] cm/10[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	AE Start Date Time/ Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 三叉神経痛 INCREASED TRIGEMINUSNEURALGIA RIGHT SIDE	*Day 90頃/ ONGOING	RCP (-)/ -/ -	HOS	GRADE 1	NR/ NC/ RCNG	MED; NONP; OTH: JANETTA SURGERY
神経系障害 顔面不全麻痺 IDIOPATHIC PERIPHERAL FACIAL NERVE PARESIS	*Day 172/ ONGOING	RCP (172)/ 172/ -	HOS	GRADE 2	NR/ NC/ RCNG	MED; NONP; OTH: SPEECH THERAPY

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Female/5[redacted] years/Asian/16[redacted].7 cm/6[redacted].9 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 蜂巣炎 CELLULITIS OF LEFT FOOT	64	RCP (106)/ 106/ 169	HOS	GRADE 2	REL/ INT/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Female/5[redacted] years/Asian/15[redacted].8 cm/4[redacted].9 kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
胃腸障害 小腸炎 SMALL INTESTINAL MUCOSITIS	10	RCP (62)/ 62/ 71	HOS	GRADE 3	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/2[redacted] years/White/18[redacted] cm/18[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
代謝および栄養障害 糖尿病性ケトアシドーシス DIABETIC KETOACIDOSIS	3	RCP (126)/ 126/ 128	HOS	GRADE 4	NR/ NC/ REC	MED

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted] (Treatment Group: Placebo/Female/5[redacted] years/White/17[redacted].2 cm/8[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
神経系障害 重症筋無力症 SHORTNESS OF BREATH DUE TO MG WORSENING	14	RCP (100)/ 100/ 113	HOS	GRADE 3	NR/ NC/ REC	OTH: PLEX ON *Day 103

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.

＊新薬承認情報提供時に置き換え

Listing 16.2.7.1.2.2
Serious Adverse Events (SAEs)
Safety Set

Patient ID: [redacted]-[redacted] (Treatment Group: Placebo/Male/5[redacted] years/White/18[redacted] cm/12[redacted] kg)

System Organ Class/ Preferred Term/ Verbatim Term	Duration (Days)	Phase(RXday)/ Start Day/ End Day	Serious Criteria	Toxicity	Relationship/ Action Taken/ Outcome	Other Action Taken
感染症および寄生虫症 ＣＯＶＩＤ－１９ COVID-19	22	OLE (357)/ 174/ 195	HOS	GRADE 3	NR/ NC/ REC	NONP
感染症および寄生虫症 ＣＯＶＩＤ－１９ COVID-19 INFECTION	1	OLE (379)/ 196/ 196	DTH, HOS	GRADE 5	NR/ NA/ FATL	N

System organ classes and preferred terms were coded using 'MedDRA 24.0'
PRE=prior to first study drug infusion; RCP=randomized-controlled period; OLE=Open-label extension period; RXday: AE onset day in reference to first study drug infusion; start day and end day are in reference to phase specific first dose. OLE begins at the start of Day 183 (Week 26) dosing. Starting with Week 26, placebo patients will begin receiving ravulizumab.
Relationship: NR=Not Related; REL= Related.
Action Taken with Study Treatment: NC=Dose Not Changed; INT=Drug Interrupted; WTHD=Drug Withdrawn; NA=Not Applicable; UNK=Unknown. Other Action Taken: N=None; MED=Medication; NONP=Non-Pharmacologic Therapy/Procedure; OTH=Other.
Outcome: NORC=Not Recovered/Not Resolved; RCSQ=Recovered/Resolved with Sequelae; RCNG=Recovering/Resolving; REC=Recovered/Resolved; FATL=Fatal; UNK=Unknown.
Seriousness Criteria: ANOM=Congenital Anomaly or Birth Defect; INCP=Persistent or Significant Disability/Incapacity; DTH=Results in Death; HOS=Requires or Prolongs Hospitalization; THRT=Is Life Threatening; OTH=Other Medically Important Serious Event.